Table 4.
AKI related characteristics and outcomes
| Variable | DI-AKI (n = 271) | Not DI-AKI (n = 43) | P-value |
|---|---|---|---|
| Previous DI-AKI, n (%) | 10 (3.7) | 2 (4.8) | 1 |
| Start of drug exposure to AKI onset, days, median (IQR) | 5 (8) | 3 (3.5) | 0.24 |
| Baseline SCr, mg/dl, mean (SD) | 0.91 (0.44) | 0.98 (0.81) | 0.60 |
| Peak SCr, mg/dl, mean (SD) | 4.5 (2.7) | 3.7 (3.2) | 0.12 |
| Discharge SCr, mg/dl, mean (SD) | 2.2 (1.5) | 2.1 (1.4) | 0.72 |
| 28-days SCr, mg/dl, mean (SD) | 1.6 (1.6) | 1.6 (1.0) | 0.96 |
| 90-days SCr, mg/dl, mean (SD) | 1.4 (2.0) | 1.5 (0.9) | 0.28 |
| AKI stage 3 during hospitalization, n (%)a | 194 (73.7) | 21 (48.8) | <0.01 |
| AKD at hospital discharge, n (%)b | 166 (61.3) | 14 (32.6) | <0.01 |
| AKD at 28 days, n (%)b | 74 (27.3) | 11 (25.6) | 1 |
| AKD at 90 days, n (%)b | 40 (14.8) | 5 (11.6) | 0.79 |
| Biopsy, n (%) | 33 (12.2) | 0 (0) | <0.01 |
| Need for KRT during hospitalization, n (%) | 70 (2.6) | 11 (2.6) | 1 |
| Duration of hospital stay, days, median (IQR) | 17 (23) | 17 (21) | 0.83 |
| Inpatient mortality, n (%) | 15 (5.5) | 4 (9.3) | 0.52 |
AKD, acute kidney disease; AKI, acute kidney injury; DI-AKI, drug-induced acute kidney injury; IQR, interquartile range; KRT, kidney replacement therapy; SCr, serum creatinine.
a
AKI Stage 3 was defined as 3 times baseline serum creatinine meeting the 2012 Kidney Disease Improving Global Outcomes criteria.
b
AKD was defined as 1.5 × baseline SCr.